PitchSend

Investor Presentaiton

Dato-DXd Path for establishing 2L/3L treatment in NSCLC TROPION-Lung 01 study Disclosed TLR in July 2023 Daiichi-Sankyo Major Ph3 Clinical Studies of Dato-DXd in NSCLC Advanced/Metastatic Advanced or Dato-DXd 6.0 mg/kg 1L 24 2L 3L Randomization metastatic 1:1 NSCLC 2L/3L Docetaxel 75 mg/m² N = 600 TROPION- Lung07 (PD-L1 <50%) Primary: PFS, OS Secondary: ORR, DOR, DCR, PK, safety etc. NSCLC without AGA Demonstrated statistically significant improvement in PFS TROPION- Lung08 (PD-L1 ≥ 50%) TROPION- Lung01 ■No new safety signals identified, all grade ILD was generally consistent with prior clinical trials with the majority being grade1 or 2. Grade 5 ILD events were observed ■Proceeding to file the data with FDA NSCLC with AGA AGA: actionable genomic alteration, DCR: Disease Control Rate, DoR: Duration of Response, FDA: U.S. Food and Drug Administration, ILD: interstitial lung disease, NSCLC: Non-small Cell Lung Cancer, ORR: Overall Response Rate, OS: Overall Survival, PFS: Progression Free Survival, PK: Pharmacokinetics, TLR: Top Line Results 22

View entire presentation